Vispacabtagene regedleucel
Cell therapy
Also known as CB-010
Evidence outlook · program status
Discontinued (2026-10-06), for financing reasons
Caribou's board approved a restructuring that discontinues the clinical trials and further development of vispa-cel and CB-011, citing the financing environment for allogeneic CAR-T. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ANTLER NCT04637763 · B-Cell Non-Hodgkin Lymphoma Registry: NCT04637763 | 1 | Primary outcome measures number of patients with dose-limiting toxicities (Part A). (28 days following CB-010 infusion); Primary outcome evaluates tumor response (Part B) (Up to 12 months) 2025-09-11 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other CD19 drugs
Inebilizumab, obecabtagene autoleucel, Tafasitamab, budoprutug, cemacabtagene ansegedleucel and 12 more. Compare all 18 CD19 drugs
This mechanism is crowded: 18 other tracked programmes target it, 17 of them ahead of this one.
This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Discontinued. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vispacabtagene Regedleucel: this drug | Discontinued | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Obecabtagene Autoleucel (Aucatzyl) | Approved(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PF-05280586 | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Tafasitamab | Approved(overall) | Monoclonal antibody | CD19 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cemacabtagene Ansegedleucel | Phase 2(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Rapcabtagene Autoleucel | Phase 2(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4512 | Phase 1/2 | Antibody–drug conjugate | CD22 | not yet graded | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| JNJ-88998377 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5837 | Phase 1 | Multispecific antibody | CD22 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3079 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-619 | —(overall) | Undisclosed | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| GLPG5101 | Discontinued | Cell therapy | CD19 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.